SURVYR

BIIB

Biogen Inc.
$244.05
−$8.68 (3.43%)Oct 28 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-8%+11%+30%+50%+69%Oct 2025Oct 2026Apr 202652w high $254.4152w low $138.00
BIIBSPY
Wall St. Highest PT $310.00 (+27.0%) Wall St. Avg PT $247.32 (+1.3%)
$148$191$234$276$319POC $189Hi $310Avg $247
Underwater Drawdown %Max DD -14.3%Current -3.9%
0.0%-14.3%
Relative Strength vs SPY+48.3% vs SPYOutperforming
+64%0%-64%
1W
+$3.07 (1.27%)
1M
+$15.36 (6.72%)
3M
+$34.82 (16.64%)
6M
+$49.67 (25.55%)
YTD
+$68.06 (38.67%)
1Y
+$94.92 (63.65%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
32 analysts · mean score 1.83
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$244.05
Average target$247.32
+$3.27 (+1.3%) upsideaverage target vs current price
CurrentAverageMedian
Low$175.00
Median$247.32
High$310.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-22 · B of A Securities reiterated Neutral on BIIB
Reiterated
2026-10-21 · TD Cowen reiterated Buy on BIIB
Reiterated
2026-10-20 · Wells Fargo reiterated Overweight on BIIB
Upgrade
2026-10-12 · JP Morgan upgraded BIIB from Neutral to Overweight
Reiterated
2026-10-09 · UBS reiterated Buy on BIIB
Reiterated
2026-10-08 · RBC Capital reiterated Outperform on BIIB
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$37.0B
P/E (last 12 months)44.5
P/E (next 12 months, estimated)15.2
52-week range$138.00 – $254.41
Revenue growth (latest quarter vs a year ago)+3.4%
Dividend yieldNo dividend
Analyst consensusBuy (32)
Average analyst price target$247.32 (+1%)

What they do

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression.

Healthcare · Drug Manufacturers - General
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
76th percentile in sector
B+
12-1 return: +46.4%
Percentile within its GICS sector across the S&P 1500.
Growth
22nd percentile in sector
D
Revenue growth (YoY): +3.4%
Percentile within its GICS sector across the S&P 1500.
Value
70th percentile in sector
B
Forward E/P: 7.1% · EBITDA/EV: 8.1%
Percentile within its GICS sector across the S&P 1500.
Profitability
43rd percentile in sector
C
Profit margin: +8.3% · Return on equity: +4.6%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 54 of 499 · 12-month momentum 54.7%
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 35 of 589 · 12-month momentum 56.4%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

BIIB earningsReports today
Next report · quarter Sep 2026
Wed Oct 28, 2026Before the open
EPS consensus$1.97 range $1.44–$2.31
Revenue consensus$2.6B 27 analysts
Last 4 quarters · EPS vs estimate
Jul 29, 2026$3.60est $2.03+77.4%Above estimates
Apr 29, 2026$3.57est $2.95+20.9%Above estimates
Feb 6, 2026$1.99est $1.62+23.2%Above estimates
Oct 30, 2025$4.81est $3.88+23.9%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-24 10:24:23 ET
24-1025-0225-0525-0725-1026-0226-0426-070.005.47
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$2.7B+3.4%
2026-03-31$2.5B–
2025-12-31$2.3B–
2025-09-30$2.5B–
2025-06-30$2.6B–

News & catalysts

More news
Biogen (BIIB) Q3 2026 Earnings Call Transcript
Nasdaq · 4h ago
Biogen Q3 26 Earnings Conference Call At 8:30 AM ET
Nasdaq · 10h ago
Biogen Slips To Loss In Q3; Raises Low-end Of FY26 Earnings View
Nasdaq · 10h ago
Biogen (BIIB) files 8-K: results
SEC 8-K · 11h ago
Biogen +5% on BofA Price Target Hike Ahead of “Relatively Quiet” Q3
TIKR · Oct 22
Rating changes
Reiterated
2026-10-22 · B of A Securities reiterated Neutral on BIIB
Reiterated
2026-10-21 · TD Cowen reiterated Buy on BIIB
Reiterated
2026-10-20 · Wells Fargo reiterated Overweight on BIIB
Upgrade
2026-10-12 · JP Morgan upgraded BIIB from Neutral to Overweight
Reiterated
2026-10-09 · UBS reiterated Buy on BIIB
Reiterated
2026-10-08 · RBC Capital reiterated Outperform on BIIB

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Minor Lloyd
Director · 2026-08-04
Sell
$119.2K
Minor Lloyd
Director · 2026-08-03
Sell
$120.6K
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-24 10:24:23 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026